Sagent raises $40M, increases reach in China

Illinois-based Sagent Pharmaceuticals announced today that it has raised $40 million through two tranches of a strategic Series B financing. A $10 million investment was made by Zhejiang Hisun Pharmaceutical, while an "unnamed China-focused private equity investment fund" contributed the other $30 million.

Sagent brings finished pharmaceutical therapies to the U.S. market with a focus on injectable products. "Sagent has gained expanded access to Hisun's extensive portfolio of active pharmaceutical ingredients and, shortly, to its finished injectable product capabilities," notes CEO Jeffrey Yordon in a statement. "In addition, Sagent's reach into China will be extended through the Chinese investment fund's strong relationships in the rapidly maturing injectable marketplace in that region."

- see Sagent's release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.